New Key Statistics Module, Z-Score and F-Score
NAS:LYRA Key Ratios
| Market Cap $ M | 11.28 |
| Enterprise Value $ M | -5.02 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 0.55 |
| Price/Sales | 7.83 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 1.00 |
| EPS (TTM) $ | -1.49 |
| Beneish M-Score | -2.25 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 0.70 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | 0.07 |
| EV-to-EBITDA | 0.07 |
| PEG | -- |
| Shares Outstanding M | 65.46 |
| Net Margin (%) | -6,635.76 |
| Operating Margin % | -4,584.91 |
| Pre-tax Margin (%) | -6,632.36 |
| Quick Ratio | 3.64 |
| Current Ratio | 3.64 |
| ROA % (ttm) | -84.43 |
| ROE % (ttm) | -161.20 |
| ROIC % (ttm) | -177.64 |
| Dividend Yield % | -- |
| Altman Z-Score | -10.35 |
LYRA Number of Guru Trades
LYRA Volume of Guru Trades
Gurus Latest Trades with NAS:LYRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:LYRA is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Lyra Therapeutics Inc Insider Transactions
No Available Data
News about NAS:LYRA
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers